http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
-
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
-
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
-
ContraFect (CFRX) to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens
-
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
-
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update
-
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
-
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
-
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
-
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
-
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
-
ContraFect (CFRX) Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
-
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
-
ContraFect (CFRX) Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
-
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
-
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
-
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
-
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
ContraFect (CFRX) Reports Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
-
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
-
ContraFect (CFRX) Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
-
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
-
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
-
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
-
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update
-
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibi
-
ContraFect (CFRX) Announces Presentations Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance
-
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
-
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
-
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
-
ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference
-
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
-
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
-
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis
-
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
-
ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia
-
ContraFect (CFRX) Selected to Present Late Breaking Phase 2 Exebacase Data at IDWeek
-
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
-
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
-
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
-
ContraFect (CFRX) Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
-
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
-
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
-
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
-
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
-
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
-
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
